CLL
Clinical trials for CLL explained in plain language.
Never miss a new study
Get alerted when new CLL trials appear
Sign up with your email to follow new studies for CLL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancers: experimental pill takes on CLL and SLL
Disease control Recruiting nowThis Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with two types of targeted therapy (BTK and BCL2 inhib…
Matched conditions: CLL
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New dosing strategy aims to reduce dangerous side effect in blood cancer treatment
Disease control Recruiting nowThis study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …
Matched conditions: CLL
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to outperform standard therapy for Hard-to-Treat blood cancers
Disease control Recruiting nowThis phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…
Matched conditions: CLL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…
Matched conditions: CLL
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New CAR-T therapy targets BAFF-R to fight resistant lymphoma
Disease control Recruiting nowThis early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-…
Matched conditions: CLL
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of a BTK inhibitor (acalabrutinib …
Matched conditions: CLL
Phase: PHASE2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Lab-Grown lymph node model reveals how CLL cells resist treatment
Knowledge-focused Recruiting nowThis study investigates how chronic lymphocytic leukemia (CLL) cells change their energy use when they are in the lymph node environment, which may help them resist standard treatments. Researchers are building a lab model using patient leukemia cells and normal lymph node cells …
Matched conditions: CLL
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive new registry to track thousands of blood cancer patients for years
Knowledge-focused Recruiting nowThis study is a registry that will follow up to 8,000 people with chronic lymphocytic leukemia (CLL) and related blood cancers over many years. It does not test a new treatment but instead collects information on how patients are doing over time, including survival. The goal is t…
Matched conditions: CLL
Sponsor: German CLL Study Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC